Can the prevention of tuberculosis reduce new coronal infections? Large sample study in Israel: Invalid

In addition to its special anti-tuberculosis effects, the card is beneficial to the immune system, helping to fight a variety of other infections and is often used to treat bladder cancer. Recently, researchers have suggested that vaccination cards may protect health care workers and other at-risk populations from the new crown.

However, a study from Israel published may 13 local time by JAMA, an international medical journal, shows that inoculation in childhood does not help avoid new crown infringements in adulthood. The paper team was from the Center for Microbiome Research, Shamir Medical Center at Shamir Medical Center in Israel.

What is special about the Israeli study is that between 1955 and 1982, as part of the national immunization programme, Israel routinely vaccinated all newborns. During that time, Israel had a high rate of vaccine acceptance, with coverage of over 90 per cent. But since 1982, Israel has only vaccinated immigrants from countries with high rates of tuberculosis. This change can be compared to similar populations, different card-mediated vaccination infection rates and the proportion of severe illness. The study selected individuals born three years before and three years after the termination of the Camconita National Vaccine Program.

The fatality rate from new coronaviruses varies from country to country. There has been speculation that one of the reasons may be related to the child card-based miao (BCG vaccine) vaccination policy in all regions of the country, countries with card-based vaccination policies, which report fewer confirmed cases and lower deaths. However, this speculation has a huge flaw: differences in new crown mortality rates in different regions are influenced by a number of potential factors, such as the outbreak phase, the average age of the affected population, disease control measures, the number of tests, and the definition or underreporting of deaths associated with COVID-19. The advantage of the Israeli study was that other mixed factors were kept to a minimum through the study and comparison of two similar age groups in a large sample.

The current policy of the Ministry of Health of Israel is to test each patient with cough, breathing difficulties and fever for new coronanucleic acid. The researchers selected the results of the nasopharyngeal swab nucleic acid test swab for the period from March 1 to April 5, 2020. The test results were layered by the year of birth of the subjects, and the relevant population data were obtained from Israel’s National Central Bureau of Statistics. The researchers used the test to see differences in the new coronal positive rates for people born between 1979 and 1981 (39-41 years) and between 1983 and 1985 (35-37 years old). The two-tailaion-near-significantity test threshold is set by P-lt;0.05.

Of the 72,060 test results, 3,064 were from patients born between 1979 and 1981 (1.02 per cent of the same population; 49.2 per cent of men; with an average age of 40 years), of whom 2,869 were from the unvaccinated population born between 1983 and 1985 (0.96 per cent of the male population; There were 361 positive swea-positive sons in the Ka-Miao vaccination group, with a rate of 11.7 per cent, and the unvaccinated group had 299 positive sons, compared with 10.4 per cent. There was no statistically significant difference in the proportion of positive test results. There was one serious illness (requiring mechanical ventilation or ICU) in both groups and none of the deaths. The results are as follows:

Can the prevention of tuberculosis reduce new coronal infections? Large sample study in Israel: Invalid

Among Israeli adults between the ages of 35 and 41, the positive rate of hives in childhood was similar to that of SARS-CoV-2, with no statistically significant difference. Because the number of severe cases in both groups is very small, it is not possible to arrive at a relationship between the relevant card-based seeding and the severity of the new crown.

In short, this study does not support the child stage vaccination card-mediated seedlings for the new crown of adulthood has a protective effect.

Bacillus Calmette Guerin, also known as BCG, began its widespread popularity in the 1920s, often used to prevent tuberculosis (TB), often referred to as the “first needle at birth”. It contains a weakened form of mycobacterium bovine, a close relative of mycobacterium tuberculosis.

Usually a vaccine causes an immune response to a specific pathogen, such as antibodies that bind and neutralize a virus, but do not suppress other types of viruses. The cacao works by promoting immune system cells in the bone marrow, which are then released to strengthen the immune system’s innate mechanisms that respond to a variety of pathogens.

The idea that The New York Institute of Technology uploaded a paper on the preprinted website medRxiv in March was not peer-reviewed.

An analysis of data from 178 countries found that in countries that had never promoted card-based seedlings, such as the United States, Italy, Belgium and the Netherlands, the incidence of new crowns was higher than in low-income countries where cacao seedlings were widely available. In addition, if the prevalence is later (e.g. in Iran), the new crown mortality rate is higher.

Subsequently, there have been international clinical trials of new crowns related to Caerme.

On March 27, the University of Melbourne in Australia announced that it would launch a clinical trial to test whether health care workers are protected after getting a card. On 31 March, the Netherlands also recruited medical staff who volunteered to vaccinate card-inoculated seedlings on the International Clinical Trials website.

The May 4 issue of the leading medical journal The Lancet, published in the Journal of the University of Melbourne, the World Health Organization, the Icahn School of Medicine at Mount Sinai in the United States, and the University of Bonn in Germany, says that while there is some evidence that card-based seedlings may be effective, who sits strictly follow WHO’s recommendationthat that they can only be used in randomized controlled trials to verify their effectiveness in mitigating the effects of the new crown. Before this validation is valid, the misuse of card-mediated seedlings may result in a series of negative reactions.

The Lancet newsletter says SARS-CoV-2 is a positive-chain RNA virus, and in controlled tests, it has been shown that cacao can reduce the severity of infection with other viruses with this structure. For example, in a volunteer trial in the Netherlands, Caerphilly reduced the viral emias of the yellow fever vaccine by 71% (95% CI 6-91). In two studies of mice, it significantly reduced the severity of the mengovirus (cerebrocarditis virus) infection.

The newsletter says many of the mechanisms that are useful for off-target effects of cacao seedlings are now known. Camenmiao and other live vaccines induce metabolic and epigenetic changes that enhance the innate immune response to their post-infection infection, a process known as training immune. As a result, the cacao vaccine may reduce viralemia after SARS-COV-2 exposure, thereby reducing the severity of COVID-19 and speeding up patient recovery.

The State Council’s joint defense and control mechanism held a press conference on April 14 to respond to recent claims by some countries that card-playing seeding could reduce the likelihood of new coronal pneumonia. Wang Junzhi, a member of the Chinese Academy of Engineering, said that foreign rumors, Ka-Miao is actually a vaccine for children’s immunization, in our country is still relatively widely used, but at present we do not see accurate research data to support this statement.